Cholecalciferol
Devikap contains the active substance cholecalciferol, which is identical to vitamin D produced in the human body.
Devikap is used:
Vitamin D deficiency may occur in people living at high geographical latitudes (> 35°) or in those whose diet or lifestyle does not provide adequate amounts of vitamin D (people who spend most of their time indoors, working at night), or when the need for vitamin D is increased (pregnant women, people with overweight and obesity).
Before starting treatment with Devikap, discuss it with your doctor or pharmacist:
Devikap can only be given to children over 11 years of age.
This medicine is best taken with the main meal to facilitate the absorption of vitamin D.
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy
Devikap should only be taken during pregnancy if prescribed by a doctor.
During pregnancy, women should follow the doctor's recommendations, as their needs may vary depending on the degree of deficiency and response to treatment.
If a woman needs additional doses of vitamin D, she should not take them without medical supervision, as too high a level of vitamin D can harm the baby.
During pregnancy, you should avoid overdosing on vitamin D, as prolonged hypercalcemia (elevated calcium levels in the blood) can lead to delayed physical and mental development, as well as congenital heart defects and eye defects in the baby.
Breastfeeding
Devikap should only be taken during breastfeeding if prescribed by a doctor.
Vitamin D and its metabolites pass into breast milk.
No overdose has been observed in breastfed infants. Breastfeeding women should not take high doses of vitamin D to supplement their baby.
Devikap is unlikely to affect your ability to drive or use machines.
Always take this medicine exactly as your doctor or pharmacist has told you. If you are not sure, ask your doctor or pharmacist.
The dosing schedule and treatment should take into account the patient's clinical condition.
Body Mass Index (BMI) is a factor that allows you to calculate whether your body mass is proportional to your height. A normal BMI is above 18.5 and less than 25 (kg/m2body surface area).
A person is considered overweight if their BMI is between 25 and 29.9 (kg/m2body surface area), and obese if their BMI is 30 (kg/m2body surface area) or more.
2,000 IU per day, as recommended by your doctor.
Obese adults (BMI ≥ 30 kg/m2)
Typically, the recommended dose is 4,000 IU per day, depending on the degree of obesity and the patient's response to treatment.
If necessary, a measurement of 25(OH)D levels should be performed after three to four months of treatment to confirm that the target 25(OH)D level has been achieved.
2,000 IU per day, as recommended by your doctor.
If necessary, a measurement of 25(OH)D levels should be performed after three to four months of treatment to confirm that the target 25(OH)D level has been achieved.
2,000 IU to 4,000 IU per day, as recommended by your doctor. In some populations (including obese adults), a higher dose may be required.
In adult patients with laboratory-confirmed vitamin D deficiency, the recommended dose is 10,000 IU per day for 1 to 3 months, and then 2,000 IU per day or 10,000 IU per week, depending on age and body weight, under medical supervision.
The doctor will re-check the 25(OH)D levels after three to four months of treatment to confirm that the target 25(OH)D level has been achieved.
Obese patients
Obese adults (BMI ≥ 30 kg/m2) may require higher doses.
Underweight patients
Adults who are underweight (BMI <18.5 kg/m2) may require lower doses.
Adolescents and children over 11 years of age
2,000 IU to 4,000 IU per day, as recommended by your doctor. Some patients (including obese adolescents and children) may require higher doses.
Treatment of vitamin D deficiency and conditions resulting from vitamin D deficiency should be continued for three months or until a 25(OH)D level of ≥30-50 ng/ml is achieved, then a maintenance dose, i.e. the recommended preventive dose for the general population, should be used, depending on age and body weight.
Obese adolescents and children over 11 years of age (BMI > 90th percentile for age)
Obese adolescents and children over 11 years of age (BMI > 90th percentile for age) may require higher doses of vitamin D than recommended for adolescents and children with normal body weight, depending on the degree of obesity.
Method of administration
The capsules should be swallowed whole with water, preferably during the main meal.
If you accidentally take one capsule more than recommended, the occurrence of overdose symptoms is unlikely.
If you have taken too much of the medicine, tell your doctor or pharmacist or contact the nearest hospital emergency department for further advice. If possible, take the package and this leaflet with you to show the doctor.
If you forget to take the medicine, take it as soon as possible. Take the next dose at the usual time. However, if it is almost time for the next dose, do not take the missed dose, just take the next dose at the usual time.
If you have any further questions about taking this medicine, ask your doctor or pharmacist.
Like all medicines, Devikap can cause side effects, although not everybody gets them.
Seek medical attention immediatelyif you experience symptoms of angioedema, such as:
Other side effects associated with Devikap include:
Uncommon(occurring in less than 1 in 100 patients)
Rare(occurring in less than 1 in 1,000 patients)
Frequency not known(cannot be estimated from the available data)
If you experience any side effects, including those not listed in this leaflet, tell your doctor or pharmacist. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products:
Aleje Jerozolimskie 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help to gather more information on the safety of this medicine.
Keep the medicine out of the sight and reach of children.
Do not store above 30°C. Store in the original package to protect from light.
Do not use this medicine after the expiry date stated on the carton and blister after EXP.
The expiry date refers to the last day of the month.
The inscription on the packaging after the abbreviation EXP indicates the expiry date, and after the abbreviation Lot/LOT indicates the batch number.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Devikap 2,000 IU: the medicine is in the form of light yellow, oval, soft capsules (short diameter approximately 6 mm) with a seam in the middle, filled with a light yellow, oily liquid.
Devikap 4,000 IU: the medicine is in the form of light yellow, oval, soft capsules (short diameter approximately 7 mm) with a seam in the middle, filled with a light yellow, oily liquid.
Devikap 10,000 IU: the medicine is in the form of light yellow, oval, soft capsules (short diameter approximately 9 mm) with a seam in the middle, filled with a light yellow, oily liquid.
Devikap 2,000 IU and Devikap 4,000 IU: the pack contains 30, 60, or 90 capsules in blisters.
Devikap 10,000 IU: the pack contains 30 or 60 capsules in blisters.
Not all pack sizes may be marketed.
Zakłady Farmaceutyczne POLPHARMA S.A.
Pelplińska 19, 83-200 Starogard Gdański
phone: +48 22 364 61 01
Zakłady Farmaceutyczne POLPHARMA S.A.
Medana Branch in Sieradz
Władysława Łokietka 10, 98-200 Sieradz
Date of last revision of the leaflet:September 2024
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.